Vimarsana
Biggest News Aggregation in the World

Page 18 - Johnson Amp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Johnson Amp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Johnson Amp Today - Breaking & Trending Today

Johnson & Johnson (NYSE:JNJ) Receives $167.87 Average PT from Analysts - Vimarsana News

Johnson & Johnson (NYSE:JNJ) Receives $167.87 Average PT from Analysts

Johnson & Johnson (NYSE:JNJ – Get Free Report) has been assigned an average rating of “Hold” from the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective […]

Bristol Myers' New Drugs Drive Upbeat Outlook. The Stock Is On the Mend. - Vimarsana News

Bristol Myers' New Drugs Drive Upbeat Outlook. The Stock Is On the Mend.

Bristol Myers Squibb’s fourth-quarter earnings and revenue beat Wall Street expectations.

Merck Stock Jumps as Earnings Beat, Guidance Ahead of Wall Street Expectations - Vimarsana News

Merck Stock Jumps as Earnings Beat, Guidance Ahead of Wall Street Expectations

Merck posted a 3-cent a share profit in the fourth quarter, beating expectations of a loss.

Florida now first state with FDA approval to import drugs - Will New York consider? - Vimarsana News

Florida now first state with FDA approval to import drugs - Will New York consider?

In an effort to find ways to make drugs more affordable, the FDA approved Florida's request last month to import certain drugs from Canada. CBS 6 dug into wheth

Johnson & Johnson (NYSE:JNJ) Updates FY 2024 Earnings Guidance - Vimarsana News

Johnson & Johnson (NYSE:JNJ) Updates FY 2024 Earnings Guidance

Johnson & Johnson (NYSE:JNJ – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 10.550-10.750 for the period, compared to the consensus earnings per share estimate of 10.670. The company issued revenue guidance of $87.8 billion-$88.6 billion, compared to the consensus […]